References
- 1. R. J. Herman, Drug interactions and the statins, CMAJ 161 (1999) 1281-1286.
- 2. Cardiovascular Drugs, in Martindale: The Complete Drug Reference, 36th ed. (Ed. S. C. Sweetman), Pharmaceutical Press, London 2009, pp. 1155-1434.
- 3. T. Uno, K. Sugimoto, K. Sugawara and T. Tateishi, The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazol, Ther. Drug Monit. 30 (2008) 276-281; DOI: 10.1097/FTD.0b013e31816e2d8e.
- 4. C. Bolego, R. Baetta, S. Bellosta, A. Corsini and R. Paoletti, Safety considerations for statins, Curr. Opin. Lipidol. 13 (2002) 637-644.
- 5. H. M. Devold, E. Molden, S. Skurtveit and K. Furu, Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy, Br. J. Clin. Pharmacol. 67 (2009) 234-241; DOI: 10.1111/j.1365-2125.2008.03345.x.
- 6. E. Molden, K. S. Andersson and D. Jacobsen, Interactions between statins and macrolide antibiotics, Tidsskr. Nor. Laegeforen 127 (2007) 1660-1661.
- 7. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paolett and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther. 84 (1999) 413-428.
- 8. C. M. White, A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin, J. Clin. Pharmacol. 42 (2002) 963-970.
- 9. R. Bhindi, O. Ormerod, J. Newton, A. P. Banning and L. Tesla, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101 (2008) 915-925; DOI: 10.1093/qjmed/ hcn089.
- 10. P. J. Neuvonen, M. Niemi and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance, Clin. Pharmacol. Ther. 80 (2006) 565-581.
- 11. K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang, Membrane transporters in drug development, Nat. Rev. Drug Discov. 9 (2010) 215-236; DOI: 10.1038/nrd3028.
- 12. M. Karlgren, G. Ahlin, C. A. Bergström, R. Svensson, J. Palm and P. Artursson, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions, Pharm. Res. 29 (2012) 411-426; DOI: 10.1007/s11095-011-0564-9.
- 13. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop and R. Collins, SLCO1B1 variants and statin-induced myopathy - a genomewide study, N. Engl. J. Med.359 (2008) 789-799; DOI: 10.1056/NEJMoa0801936.
- 14. D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury and G. S. Ginsburg, The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J. Am. Coll. Cardiol. 54 (2009) 1609-1616; DOI: 10.1016/j.jacc.2009.04.053.
- 15. J. P. F. Bai, Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics, Drug Metab. Pharmacokin. 25 (2010) 62-71.
- 16. J. Mwinyi, A. Johne, S. Bauer, I. Roots and T. Gerloff, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetic, Clin. Pharmacol. Ther. 75 (2004) 415-421.
- 17. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum and K. T. Kivistö, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics 14 (2004) 429-440.
- 18. Y. Shitara, Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions, Drug Metab. Pharmacokin. 26 (2011) 220-227; DOI: 10.2133/dmpk.DMPK-10-RV-094.
- 19. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa and K. Chib, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokin. 19 (2004) 453-455.
- 20. Y. Y. Lau, H. Okochi, Y. Huang and L. Z. Benet, Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems, J. Pharmacol. Exp. Ther. 316 (2006) 762-771.
- 21. G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman and Y. Elhawi, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir, J. Am. Board. Fam. Med. 20 (2007) 411-416.
- 22. V. Borders-Hemphill, Concurrent use of statins and amiodarone, Consult. Pharm. 24 (2009) 372-379.
- 23. S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann. Pharmacother. 42 (2008) 1037-1047; DOI: 10.1345/aph.1K628.
- 24. D. Williams and J. Freely, Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors, Clin. Pharmacokinet. 41 (2002) 343-370.
- 25. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (2004) III50-III57; DOI: 10.1161/01.CIR.0000131519.15067.1f.
- 26. K. Ohyama, M. Nakajima, M. Suzuki, N. Shimada, H. Yamazaki and T. Yokoi, Inhibitory effects of amiodarone and its N-desethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions, Br. J. Clin. Pharmacol. 49 (2000) 244-253.
- 27. U. M. Chouhan, S. Chakrabarti and L. J. Millward, Simvastatin interaction with clarithromycin and amiodarone causing myositis, Ann. Pharmacother. 39 (2005) 1760-1761.
- 28. A. Marot, J. Morelle, V. A. Chouinard, M. Jadoul, M. Lambert and N. Demoulin, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature, Acta Clin. Belg. 66 (2011) 134-136.
- 29. B. Ricaurte, A. Guirguis, H. C. Taylor and D. Zabriskie, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity, Ann. Pharmacother. 40 (2006) 753-757.
- 30. A. Alsheikh-Ali and R. Karas, Adverse events with concomitant amiodarone and statin therapy, Prev. Cardiol. 8 (2005) 95-97.
- 31. S. Karimi, A. Hough, C. Beckey and D. Parra, Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center, J. Manag. Care Pharm. 16 (2010) 472-481.
- 32. DRUGDEX®/MICROMEDEX®. Statins. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2012. Retrieved from:http://www.thomsonhc.com/home/dispatch (accessed July 6, 2012).
- 33. G. W. Amsden, O. Kuye and G. C. Wei, A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers, J. Clin. Pharmacol. 42 (2002) 444-449.
- 34. G. W. Amsden, Macrolides versus azalides: a drug interaction update, Ann. Pharmacother. 29 (1995) 906-917.
- 35. M. P. Pai, D. M. Graci and G. W. Amsden, Macrolide drug interactions: an update, Ann. Pharmacother.34 (2000) 495-513.
- 36. J. W. Grunden and K. A. Fisher, Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin, Ann. Pharmacother. 31 (1997) 859-863.
- 37. M. Z. Skrabal, J. A. Stading, C. A. Cannella and M. S. Monaghan, Two cases of rhabdomyolysis associated with high-dose simvastatin, Am. J. Health. Syst. Pharm. 60 (2003) 578-581.
- 38. J. Strandell, A. Bate, S. Hägg and I. R. Edwards, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction, Br. J. Clin. Pharmacol. 68 (2009) 427-434; DOI: 10.1111/j. 1365-2125.2009.03473.x.
- 39. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood and G. R. Wilkinson, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res. 16 (1999) 408-414.
- 40. C. Marzolini, E. Paus, T. Buclin and R. B. Kim, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin. Pharmacol. Ther. 75 (2004) 13-33.
- 41. S. Eberl, I. Bachmakov, F. Dörje and M. F. Fromm, The effect of macrolide antibiotics on the function of the drug transporter P-glycoprotein, Naunyn-Schmiedeberg’s Arch. Pharmacol. 371 (2005) R145.
- 42. J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack and W. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction, Br. J. Clin. Pharmacol. 56 (2003) 32-38.
- 43. T. Jacobson, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors, Am. J. Cardiol. 94 (2004) 1140-1146.
- 44. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dörje, M. F. Fromm and J. König, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3, Drug Metab. Dispos. 35 (2007) 779-786.
- 45. M. Hirano, K. Maeda, Y. Shitara and Y. Sugiyama, Drug-drug interaction between pitavastatin and various drugs via OATP1B1, Drug Metab. Dispos. 34 (2006) 1229-1236.
- 46. R. D. Sawant, Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin, Can. J. Clin. Pharmacol. 16 (2009) 78-79.
- 47. M. Ishigami, M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito and Y. Sugiyama, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions, Pharm. Res. 18 (2001) 622-631.
- 48. K. T. Kivistö, T. Kantola and P. J. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, Br. J. Clin. Pharmacol. 46 (1998) 49-53.
- 49. K. Akram, S. Rao and M. Parker, A lesson for everyone in drug-drug interactions (letter), Int. J. Cardiol. 118 (2007) 19-20.
- 50. R. Gilad and Y. Lampl, Rhabdomyolysis induced by simvastatin and ketoconazole treatment, Clin. Neuropharmacol. 22 (1999) 295-297.
- 51. H. Itakura, D. Vaughn, D. Haller and P. O’Dwyer, Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer, J. Urol. 169 (2003) 613; DOI: 10. 1016/S0022-5347(05)63967-5.
- 52. C. Stein, S. Goel and R. Ghavamian, Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy, Invest. New Drugs25 (2007) 277-278.
- 53. O. Findling, N. Meier, J. Sellner, K. Nedeltchev and M. Arnold, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole, Neurology 71 (2008) 34-37; DOI: 10.1212/01.wnl.0000327566.57661.09.
- 54. C. C. Franz, M. Bruggisser, S. Krähenbühl and A. E. Rätz Bravo, Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole, Praxis (Bern 1994) 100 (2011) 273-284; DOI: 10.1024/1661-8157/a000491.
- 55. R. Hazin, J. Y. Abuzetun, M. Suker and J. Porter, Rhabdomyolysis induced by simvastatin-fluconazole combination, J. Natl. Med. Assoc. 100 (2008) 444-446.
- 56. A. Shaukat, M. Benekli, G. D. Vladutiu, J. L. Slack, M. Wetzler and M. R. Baer, Simvastatin-fluconazole causing rhabdomyolysis, Ann. Pharmacother. 37 (2003) 1032-1035.
- 57. N. E. Azie, D. C. Brater, P. A. Becker, D. R. Jones and S. D. Hall, The interaction of diltiazem with lovastatin and pravastatin, Clin. Pharmacol. Ther. 64 (1998) 369-377.
- 58. O. Mousa, D. C. Brater, K. J. Sunblad and S. D. Hall, The interaction of diltiazem with simvastatin, Clin. Pharmacol. Ther. 67 (2000) 267-274.
- 59. Y. Sugiyama, N. Mimura, T. Kuwabara, H. Kobayashi, J. Ushiki and E. Fuse, Effect of benidipine on simvastatin metabolism in human liver microsomes, Drug Metab. Pharmacokinet. 22 (2007) 199-205.
- 60. J. J. Lewin, J. M. Nappi and M. H. Taylor, Rhabdomyolysis with concurrent atorvastatin and diltiazem, Ann. Pharmacother. 36 (2002) 1546-1549.
- 61. R. Peces and A. Pobes, Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem, Nephron. 89 (2001) 117-118.
- 62. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin and T. A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, Br. J. Clin. Pharmacol. 47 (1999) 291-298.
- 63. M. Jasiñska, J. Owczarek and D. Orszulak-Michalak, The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study, Acta Pol. Pharm. 63 (2006) 386-390.
- 64. T. Kantola, K. T. Kivisto and P. J. Neuvonen, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 64 (1998) 177-182.
- 65. H. Satoh, F. Yamashita, M. Tsujimoto, H. Murakami, N. Koyabu, H. Ohtani and Y. Sawada, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B, DrugMetab. Dispos. 33 (2005) 518-523.
- 66. P. Li, P. S. Callery, L. S. Gan and S. K. Balani, Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction, Drug Metab. Dispos. 35 (2007) 1203-1208.
- 67. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin, Clin. Pharmacol. Ther. 66 (1999) 118-127.
- 68. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors, Clin. Pharmacol. Ther. 64 (1998) 477-483.
- 69. J. J. Lilja, M. Neuvonen and P. J. Neuvonen, Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin, Br. J. Clin. Pharmacol. 58 (2004) 56-60.
- 70. I. Fukazawa, N. Uchida, E. Uchida and H. Yasuhara, Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese, Br. J. Clin. Pharmacol. 57 (2003) 448-455.
- 71. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko and A. Fujimura, Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin, Br. J. Pharmacol. 60 (2005) 494-497.
- 72. Y. Koitabashi, T. Kumai, N. Matsumoto and M. Watanabe, Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects, Life Sci. 78 (2006) 2852-2859.
- 73. A. V. Sorokin, B. Duncan, R. Panetta and P. D. Thompson, Rhabdomyolysis associated with pomegranate juice consumption, Am. J. Cardiol. 98 (2006) 705-706.
- 74. T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima and Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine, J. Clin. Ther. Med. 19 (2003) 381-389.
- 75. Y. Shitara, T. Itoh, H. Sato, A. P. Li and Y. Sugiyam, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A, J. Pharmacol. Exp. Ther. 304 (2003) 610-616.
- 76. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass and D. W. Schneck, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther. 76 (2004) 167-177.
- 77. J. Tong, G. Laport and R. Lowsky, Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma, Bone Marrow Transplant. 36 (2005) 739-740.
- 78. A. Lasocki, B. Vote, R. Fassett and E. Zamir, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis, Ocul. Immunol. Inflamm. 15 (2007) 345-346.
- 79. S. Vives, M. Batlle, E. Montané and J. M. Ribera, Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient, Med. Clin. (Barc). 131 (2008) 676.
- 80. J. W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. März, D. Seidel, S. Schüler and W. Gross, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A, Int. J. Clin. Pharmacol. Therapeut. 40 (2002) 439-450.
- 81. M. Veeraputhiran and M. Sundermeyer, Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin, Clin. Lung Cancer 9 (2008) 232-234; DOI: 10.3816/CLC. 2008.n.036.
- 82. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis and C. S. Flordellis, Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients, Indian J. Pharmacol. 43 (2011) 385-388; DOI: 10.4103/0253-7613.83106.
- 83. R. H. Jacobson, P. Wang and C. J. Glueck, Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone, JAMA. 277 (1997) 296-297.
- 84. N. S. Karnik and J. R. Maldonado, Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminiti, Psychosomatics46 (2005) 565-568.
- 85. Serzone (nefazodone hydrochloride) US prescribing information, Bristol-Myers Squibb Company, January 2005.
- 86. C. B. Hare, M. P. Vu, C. Grunfeld and H. W. Lampiris, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death, Clin. Infect. Dis. 35 (2002) 111-112.
- 87. P. E. Sax, Strategies for management and treatment of dyslipidemia in HIV/AIDS, AIDS Care 18 (2006) 149-157.
- 88. P. H. Hsyu, M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis and B. M. Kerr, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin, Antimicrob. Agents Chemother. 4 (2001) 3445-3450.
- 89. R. A. Carr, A. K. Andre, R. J. Bertz, W. Lam, M. Chang, P. Chen, P. Williams, B. Bernstein and E. Sun, Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin, 40th ICAAC, Toronto, September 2000, presentation 1644.
- 90. C. J. Fichtenbaum, J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, F. Aweeka and NIAID AIDS Clinical Trials Group, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, AIDS 16 (2002) 569-577.
- 91. J. A. Aberg, S. L. Rosenkranz, C. J. Fichtenbaum, B. L. Alston, S. W. Brobst, Y. Segal, J. G. Gerber and ACTG A5108 team, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108, AIDS 20 (2006) 725-729.
- 92. P. A. Pham, C. J. la Porte L. S., Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner and D. W. Cameron, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers, Antimicrob. Agents Chemother. 53 (2009) 4385-4392; DOI: 10.1128/AAC.00449-09.
- 93. R. Stern, R. Abel, G. L. Gibson and J. Besserer, Atorvastatin does not alter the anticoagulant activity of warfarin, J. Clin. Pharmacol. 37 (1997) 1062-1064.
- 94. H. Hickmott, H. Wynne and F. Kamali, The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements, Thromb. Haemost. 89 (2003) 949-950.
- 95. J. C. Lin, M. K. Ito, S. N. Stolley, A. P. Morreale and D. B. Marcus, The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, J. Clin. Pharmacol. 39 (1999) 86-90.
- 96. E. A. Sconce, T. I. Khan, A. K. Daly, H. A. Wynne and F. Kamali, The impact of simvastatin on warfarin disposition and dose requirements, J. Thromb. Haemost. 4 (2006) 1422-1424.
- 97. T. Westergren, P. Johansson and E. Molden, Probable warfarin-simvastatin interaction, Ann. Pharmacother. 41 (2007) 1292-1295.
- 98. S. Ahmad, Lovastatin warfarin interaction, Arch. Intern. Med. 150 (1990) 2407.
- 99. H. S. Hoffman, The interaction of lovastatin and warfarin, Conn. Med. 56 (1992) 107.
- 100. E. A. Iliadis and M. F. Konwinski, Lovastatin during warfarin therapy resulting in bleeding, PAMed. 98 (1995) 31.
- 101. S. S. Kline and C. C. Harrell, Potential warfarin-fluvastatin interaction, Ann. Pharmacother. 31 (1997) 790.
- 102. L. E. Trilli, C. L. Kelley, S. L. Aspinall and B. A. Kroner, Potential interaction between warfarin and fluvastatin, Ann. Pharmacother. 30 (1996) 1399-1402.
- 103. M. J. Murphy and M. H. Dominiczak, Efficacy of statin therapy: possible effect of phenytoin, Postgrad. Med. J. 75 (1999) 359-360.
- 104. K. M. Tan, J. G. Kelly and K. McGarry, Statins and phenytoin interact - a case history, Br. J. Clin. Pharmacol. 65 (2008) 147-148.
- 105. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 68 (2000) 592-597.
- 106. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects, Br. J. Clin. Pharmacol. 57 (2004) 181-187.
- 107. R. Eggertsen, A. Andreasson and L. Andrén, Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin, Scand. J. Prim. Health Care 25 (2007).
- 108. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada, M. Arakawa, K.\ Sakamoto, M. Masada, I. Miyamori and A. Fujimura, Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin, Clin. Pharmacol. Ther. 70 (2001) 518-524.
- 109. W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. Carville, K. E. Guyer and E. R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation 107 (2003) 32-37.
- 110. A. Blagojevic, J. A. Delaney, L. E. Lévesque, N. Dendukuri, J. F. Boivin and J. M. Brophy, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study, Pharmacoepidemiol. Drug Saf. 18 (2009) 362-369; DOI: 10.1002/pds.1716.
- 111. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schömig and A. Kastrati, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting, Eur. Heart J. 25 (2004) 1898-1902.
- 112. J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos and A. D. Tselepis, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes, Circulation 109 (2004) 1335-1338.
- 113. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg and M. Gawaz, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation 108 (2003) 2195-2197.
- 114. J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K. H. Mak, K. Fox and E. J. Topol, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J. Am. Coll. Cardiol. 50 (2007) 291-295.
- 115. V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J. F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O’Connor and C. H. Hennekens, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch. Intern. Med. 164 (2004) 2051-2057.
- 116. P. Vinholt, T. S. Poulsen, L. Korsholm, S. R. Kristensen, J. Hallas, P. Damkier and H. Mickley, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease, Thromb. Haemost. 94 (2005) 438-443.
- 117. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D. A. Tsakiris and S. Krähenbühl, Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro, Br. J. Pharmacol.161 (2010) 393-404; DOI: 10.1111/j.1476-5381.2010.00881.x.
- 118. L. R. Whitfield, A. R. Porcari, C. Alvey, R. Abel, W. Bullen and D. Hartman, Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin, J. Clin. Pharmacol. 51 (2011) 378-388; DOI: 10.1177/0091270010366446.
- 119. J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman and P. J. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes, Drug Metab. Dispos. 30 (2002) 1352-1356.
- 120. X. Wen, J. S. Wang, J. T. Backman, K. T. Kivistö and P. J. Neuvonen, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9, Drug Metab. Dispos. 29 (2001) 1359-1361.
- 121. H. Fujino, I. Yamada, S. Shimada, M. Hirano, Y. Tsunenari and J. Kojima, Interaction between fibrates and statins - metabolic interactions with gemfibrozil, Drug Metabol. Drug Interact. 19 (2003) 161-176.
- 122. J. T. Backman, C. Kyrklund, K. T. Kivistö, J. S. Wang and P. J. Neuvonen, Plasma concentrations of active simvastatin acid are increased by gemfibrozil, Clin. Pharmacol. Ther. 68 (2000) 122-129.
- 123. T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams and C. M. Loi, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid, Drug Metab. Dispos. 35 (2007) 1315-1324.
- 124. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate, Clin. Pharmacol. Ther. 69 (2001) 340-345.
- 125. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance, Clin. Pharmacol. Ther. 73 (2003) 538-544.
- 126. P. Mathew, T. Cuddy, W. G. Tracewell and D. Salazar, An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers, Clin. Pharmacol. Ther. 75 (2004) 33.
- 127. J. D. Spence, C. E. Munoz, L. Hendricks, L. Latchinian and H. E. Khouri, Pharmacokinetics of the combination of fluvastatin and gemfibrozil, Am. J. Cardiol. 76 (1995) 80A-83A.
- 128. N. Bizzaro, E. Bagolin, L. Milani, C. Cereser and B. Finco, Massive rhabdomyolysis and simvastatin, Clin. Chem. 38 (1992) 1504.
- 129. R. A. Boyd, R. H. Stern, B. H. Stewart, X. Wu, E. L. Reyner, E. A. Zegarac, E. J. Randinitis and L. Whitfield, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol. 40 (2000) 91-98.
- 130. C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. März, J. P. Reckless and E. A. Stein, Risk for myopathy with statin therapy in high-risk patients, Arch. Intern. Med. 163 (2003) 553-564.
- 131. P. D. Thompson, P. Clarkson and R. H. Karas, Statin-associated myopathy, JAMA 289 (2003) 1681-1690.